TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-1)
Brief Summary: This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.


Options:
A: Arm Label: BTX-A-HAC NG; Type: EXPERIMENTAL; Interventions: Biological: Botulinum toxin type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): BTX-A-HAC NG | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: DaxibotulinumtoxinA 40 units; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxins, Type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebos | Intervention Type: BIOLOGICAL; Name: Botulinum Toxins, Type A; Assigned to Arm(s): DaxibotulinumtoxinA 40 units | Intervention Type: BIOLOGICAL; Name: Placebos; Assigned to Arm(s): Placebo
C: Arm Label: DaxibotulinumtoxinA 40 units; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxins, Type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebos | Intervention Type: BIOLOGICAL; Name: Botulinum Toxins, Type A; Assigned to Arm(s): DaxibotulinumtoxinA 40 units | Intervention Type: BIOLOGICAL; Name: Placebos; Assigned to Arm(s): Placebo
D: Arm Label: Dose A; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Dose B; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Dose C; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Dose D; Type: ACTIVE_COMPARATOR; Interventions: Biological: Active Comparator botulinum toxin | Arm Label: Dose E; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Comparator | Intervention Type: BIOLOGICAL; Name: Botulinum Toxin Type A; Assigned to Arm(s): Dose A, Dose B, Dose C | Intervention Type: BIOLOGICAL; Name: Active Comparator botulinum toxin; Assigned to Arm(s): Dose D | Intervention Type: BIOLOGICAL; Name: Placebo Comparator; Assigned to Arm(s): Dose E

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-2)
Brief Summary: This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.


Options:
A: Arm Label: DaxibotulinumtoxinA 40 units; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxins, Type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebos | Intervention Type: BIOLOGICAL; Name: Botulinum Toxins, Type A; Assigned to Arm(s): DaxibotulinumtoxinA 40 units | Intervention Type: BIOLOGICAL; Name: Placebos; Assigned to Arm(s): Placebo
B: Arm Label: Dose A; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Dose B; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Dose C; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Dose D; Type: ACTIVE_COMPARATOR; Interventions: Biological: Active Comparator botulinum toxin | Arm Label: Dose E; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Comparator | Intervention Type: BIOLOGICAL; Name: Botulinum Toxin Type A; Assigned to Arm(s): Dose A, Dose B, Dose C | Intervention Type: BIOLOGICAL; Name: Active Comparator botulinum toxin; Assigned to Arm(s): Dose D | Intervention Type: BIOLOGICAL; Name: Placebo Comparator; Assigned to Arm(s): Dose E
C: Arm Label: BTX-A-HAC NG; Type: EXPERIMENTAL; Interventions: Biological: Botulinum toxin type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): BTX-A-HAC NG | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: DaxibotulinumtoxinA 40 units; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxins, Type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebos | Intervention Type: BIOLOGICAL; Name: Botulinum Toxins, Type A; Assigned to Arm(s): DaxibotulinumtoxinA 40 units | Intervention Type: BIOLOGICAL; Name: Placebos; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial
Brief Summary: The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) is a 2-arm, multi-center, prospective, randomized, open-labeled, blinded-endpoint trial. The purpose of this trial is to test whether a treatment program aimed at reducing systolic blood pressure (SBP) to a lower goal (\<130 mmHg, intensive treatment) than currently recommended (\<150 mmHg, standard treatment) will reduce CVD risk among persons between 60-80 years of old. Furthermore, this trial will also examine the effect of blood pressure APP management strategy via WeChat network on medication compliance, blood pressure control and CVD benefits.


Options:
A: Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP control | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Intervention Type: DRUG; Name: Intensive BP control; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Educational Intervention | Arm Label: No Intervention Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational Intervention; Assigned to Arm(s): Intervention Group
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist CVD | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pharmacist CVD; Assigned to Arm(s): Arm 1
D: Arm Label: Weekly SMS, brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Weekly SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Intervention Type: BEHAVIORAL; Name: Short Message Services to Support ARV therapy adherence; Assigned to Arm(s): Control Group, Daily SMS, Brief message, Daily SMS, Long Message, Weekly SMS, Long Message, Weekly SMS, brief message

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial
Brief Summary: The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) is a 2-arm, multi-center, prospective, randomized, open-labeled, blinded-endpoint trial. The purpose of this trial is to test whether a treatment program aimed at reducing systolic blood pressure (SBP) to a lower goal (\<130 mmHg, intensive treatment) than currently recommended (\<150 mmHg, standard treatment) will reduce CVD risk among persons between 60-80 years of old. Furthermore, this trial will also examine the effect of blood pressure APP management strategy via WeChat network on medication compliance, blood pressure control and CVD benefits.


Options:
A: Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP control | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Intervention Type: DRUG; Name: Intensive BP control; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control
B: Arm Label: strict control; Type: ACTIVE_COMPARATOR; Interventions: Other: target blood pressure | Arm Label: moderate control; Type: ACTIVE_COMPARATOR; Interventions: Other: target blood pressure | Intervention Type: OTHER; Name: target blood pressure; Assigned to Arm(s): moderate control, strict control
C: Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP
D: Arm Label: felodipine group, active, pill; Type: ACTIVE_COMPARATOR; Interventions: Drug: Felodipine | Arm Label: placebo, no treatment, pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Felodipine; Assigned to Arm(s): felodipine group, active, pill | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo, no treatment, pill

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Auricular Acupressure for Hemodialysis Patients With Insomnia: Study Protocol for a Multi-centre Double-blind, Randomized Controlled Trial
Brief Summary: Auricular acupressure therapy (AAT) has been applied in MHD patients with insomnia in recent years and yielded favorable results. However, the effect and safety of AAT for insomnia in MHD population still lacks high quality evidence. A randomized controlled clinical trial is planned to evaluate the effect and safety of AAT in MHD patients with insomnia.


Options:
A: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group
B: Arm Label: Auricular acupressure therapy; Type: EXPERIMENTAL; Interventions: Other: auricular acupressure therapy | Arm Label: sham auricular acupressure therapy; Type: SHAM_COMPARATOR; Interventions: Other: sham auricular acupressure therapy | Intervention Type: OTHER; Name: auricular acupressure therapy; Assigned to Arm(s): Auricular acupressure therapy | Intervention Type: OTHER; Name: sham auricular acupressure therapy; Assigned to Arm(s): sham auricular acupressure therapy
C: Arm Label: Bright Light Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Bright Light Therapy | Arm Label: Wait-list intervention; Type: OTHER; Interventions: Behavioral: Wait-list intervention | Intervention Type: BEHAVIORAL; Name: Bright Light Therapy; Assigned to Arm(s): Bright Light Therapy | Intervention Type: BEHAVIORAL; Name: Wait-list intervention; Assigned to Arm(s): Wait-list intervention
D: Arm Label: extended hours; Type: EXPERIMENTAL; Interventions: Procedure: haemodialysis | Arm Label: standard hours; Type: ACTIVE_COMPARATOR; Interventions: Procedure: haemodialysis | Intervention Type: PROCEDURE; Name: haemodialysis; Assigned to Arm(s): extended hours, standard hours

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of The Effect of Fecal Microbiota Transplantation on Ulcerative Colitis and Its Mechanism
Brief Summary: Ulcerative colitis is a common digestive system disease, the incidence is increasing in recent years.It is reported that the occurrence and development of ulcerative colitis is closely related to imbalance of intestinal flora .Moreover,intestinal mucosal immunity may be related to intestinal flora. Fecal microbiota transplantation as a new technology to rebuild intestinal flora has been used for several disease，but the efficacy of ulcerative colitis by fecal microbiota transplantation needs to be further explored.


Options:
A: Arm Label: faecal microbiota filtrate; Type: EXPERIMENTAL; Interventions: Drug: encapsulated faecal microbiota filtrate | Arm Label: faecal microbiota; Type: ACTIVE_COMPARATOR; Interventions: Drug: encapsulated faecal microbiota | Arm Label: Placebo; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: encapsulated faecal microbiota filtrate; Assigned to Arm(s): faecal microbiota filtrate | Intervention Type: DRUG; Name: encapsulated faecal microbiota; Assigned to Arm(s): faecal microbiota | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Treatment in part 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Fecal Microbiota Transplantation | Arm Label: Placebo in part 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal Saline | Intervention Type: OTHER; Name: Fecal Microbiota Transplantation; Assigned to Arm(s): Treatment in part 1 | Intervention Type: OTHER; Name: Normal Saline; Assigned to Arm(s): Placebo in part 2
C: Arm Label: Metronidazole+doxycylcine+terbinafine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metronidazole, Drug: Doxycycline, Drug: Terbinafine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole+doxycylcine+terbinafine | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Metronidazole+doxycylcine+terbinafine | Intervention Type: DRUG; Name: Terbinafine; Assigned to Arm(s): Metronidazole+doxycylcine+terbinafine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fecal microbiota transplantation; Type: EXPERIMENTAL; Interventions: Procedure: FMT | Arm Label: Traditional treatments; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: FMT; Assigned to Arm(s): Fecal microbiota transplantation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Towards Optimization of Traumatic Cognitive-behavioral Therapy for Treatment of Post-traumatic Stress Disorder and Related Problems
Brief Summary: The purpose of this study is to evaluate the efficacy of a form of cognitive behavioral therapy (CBT) in a population of individuals with PTSD and common related problems (depression, anxiety or sleep disorders, pain, psychosocial stressors, low social support, substance use disorder). Half of the participants will receive a cognitive behavioral therapy with specific modules for the treatment of related problems (CBT-E) and the other half of participants will receive therapy without specific modules (CBT-C).

The main assumption is that participants treated in the CBT-E condition will present a lower level of symptom intensity of PTSD and a higher remission rate than those in the CBT-C condition during the post-treatment assessment. As a secondary objective, an analysis of the different parameters of effectiveness of the two forms of CBT (e.g., average number of sessions required to reach remission, treatment strategies used) will be performed.


Options:
A: Arm Label: Control - VSLA; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control - Mental Health; Type: OTHER; Interventions: Behavioral: Treatment as usual | Arm Label: Voluntary Savings/Loans Assoc; Type: EXPERIMENTAL; Interventions: Behavioral: Voluntary Savings/Loans Assoc | Arm Label: Cognitive Processing Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Control - Mental Health | Intervention Type: BEHAVIORAL; Name: Voluntary Savings/Loans Assoc; Assigned to Arm(s): Voluntary Savings/Loans Assoc | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Cognitive Processing Therapy
B: Arm Label: Brief Cognitive Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Cognitive Therapy | Arm Label: Assessment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief Cognitive Therapy; Assigned to Arm(s): Brief Cognitive Intervention
C: Arm Label: Online intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Online intervention | Arm Label: Psycho-educational website; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psycho-educational website | Intervention Type: BEHAVIORAL; Name: Online intervention; Assigned to Arm(s): Online intervention | Intervention Type: BEHAVIORAL; Name: Psycho-educational website; Assigned to Arm(s): Psycho-educational website
D: Arm Label: CBT-E; Type: EXPERIMENTAL; Interventions: Behavioral: Specific Modules, Behavioral: Cognitive behavioral therapy | Arm Label: CBT-C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy | Intervention Type: BEHAVIORAL; Name: Specific Modules; Assigned to Arm(s): CBT-E | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): CBT-C, CBT-E

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Towards Optimization of Traumatic Cognitive-behavioral Therapy for Treatment of Post-traumatic Stress Disorder and Related Problems
Brief Summary: The purpose of this study is to evaluate the efficacy of a form of cognitive behavioral therapy (CBT) in a population of individuals with PTSD and common related problems (depression, anxiety or sleep disorders, pain, psychosocial stressors, low social support, substance use disorder). Half of the participants will receive a cognitive behavioral therapy with specific modules for the treatment of related problems (CBT-E) and the other half of participants will receive therapy without specific modules (CBT-C).

The main assumption is that participants treated in the CBT-E condition will present a lower level of symptom intensity of PTSD and a higher remission rate than those in the CBT-C condition during the post-treatment assessment. As a secondary objective, an analysis of the different parameters of effectiveness of the two forms of CBT (e.g., average number of sessions required to reach remission, treatment strategies used) will be performed.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present-Centered Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Present-Centered Therapy; Assigned to Arm(s): Arm 2
B: Arm Label: CBT for PTSD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for PTSD | Arm Label: Imagery Rehearsal Therapy + CBT for PTSD; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy for PTSD, Behavioral: Imagery Rehearsal Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for PTSD; Assigned to Arm(s): CBT for PTSD, Imagery Rehearsal Therapy + CBT for PTSD | Intervention Type: BEHAVIORAL; Name: Imagery Rehearsal Therapy; Assigned to Arm(s): Imagery Rehearsal Therapy + CBT for PTSD
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cognitive Behavioral Treatment for Insomnia (CBT-I) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cognitive Behavioral Treatment for Insomnia (CBT-I); Assigned to Arm(s): 1
D: Arm Label: CBT-E; Type: EXPERIMENTAL; Interventions: Behavioral: Specific Modules, Behavioral: Cognitive behavioral therapy | Arm Label: CBT-C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy | Intervention Type: BEHAVIORAL; Name: Specific Modules; Assigned to Arm(s): CBT-E | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): CBT-C, CBT-E

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter STudy to Evaluate the Effect of Secukinumab 300 mg s.c. Administered During 52 Weeks to Patients Suffering From New-onset Moderate to Severe Plaque Psoriasis as Early Intervention Compared to Standard Treatment With Narrow-band UVB (STEPIn Study)
Brief Summary: The purpose of this study was to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom-free periods by preventing reactivation of old lesions or ultimately totally hindering the occurrence of new lesions, i.e., changing the natural course of the disease (Main Study).


Options:
A: Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Narrow-band ultraviolet B (nb-UVB); Type: ACTIVE_COMPARATOR; Interventions: Radiation: nb-UVB | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Secukinumab 300 mg | Intervention Type: RADIATION; Name: nb-UVB; Assigned to Arm(s): Narrow-band ultraviolet B (nb-UVB)
B: Arm Label: Immediate Methotrexate Cessation; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Gradual Reduction of Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Methotrexate | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Gradual Reduction of Methotrexate, Immediate Methotrexate Cessation | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Gradual Reduction of Methotrexate
C: Arm Label: CP 690,550 5 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 5 mg | Arm Label: CP 690,550 10 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 10 mg | Arm Label: Placebo BID+Etanercept 50 mg BIW; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept 50 mg | Arm Label: Placebo BID+Placebo BIW; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP 690,550 5 mg; Assigned to Arm(s): CP 690,550 5 mg BID+Placebo BIW | Intervention Type: DRUG; Name: CP 690,550 10 mg; Assigned to Arm(s): CP 690,550 10 mg BID+Placebo BIW | Intervention Type: BIOLOGICAL; Name: Etanercept 50 mg; Assigned to Arm(s): Placebo BID+Etanercept 50 mg BIW | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo BID+Placebo BIW
D: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A